Product name: Thymosinα1
Organism: Human
Synonyms: Thymosin alpha 1,
CAS NO.: 62304-98-7
Sequence: Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn
Modifications: N-terminal acetylation,
M.W: C129H215N33O55
M.F.: 3108.28
Purity: 95% by HPLC
Counter ion: Trifluoacetate
Format: Lyophilized powder
Description: Thymosin alpha 1 (Tα1), a 28-amino acid peptide, was first described and characterized from calf thymuses in 1977. This peptide can enhance T-cell, dendritic cell (DC) and antibody responses, modulate cytokines and chemokines production and block steroid-induced apoptosis of thymocytes. Due to its pleiotropic biological activities, Tα1 has gained increasing interest in recent years and has been used for the treatment of various diseases in clinic. Increasing evidence showed invariant NKT cells (iNKT cell) are an attractive candidate for cancer immunotherapy, but its role in colorectal cancer treatment was still unclear. Here we reported iNKT cells exerted moderate cytotoxic effect against colorectal cancer cells (CRC cells) with the stimulation of α-Galcer, and the mutual recognition between CRC and iNKT cells could be greatly enhanced by Thymosinα1 (TA), which resulted in stronger killing efficiency both in vitro and in vivo.
Uniprot ID: P06454
Usage: For Scientific Research Use Only, Not for Human Use.
Reference:
Cancer Letters, Volume 356, Issue 2, Part B, 28 January 2015, Pages 579-588.
International Immunopharmacology, Volume 15, Issue 3, March 2013, Pages 646-653.
Vaccine, Volume 30, Issue 6, 1 February 2012, Pages 1170-1180.
Peptides, Volume 31, Issue 11, November 2010, Pages 2151-2158.
Biochemical and Biophysical Research Communications, Volume 416, Issues 3–4, 16 December 2011, Pages 356-361.
International Journal of Immunopharmacology, Volume 22, Issue 12, December 2000, Pages 1067-1076.
